Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Randomized Controlled Trial ...

Integration of Telemedicine Consultation Into a Tertiary Radiation Oncology Department: Predictors of Use, Treatment Yield, and Effects on Patient Population Using the scoping review methodology ...

Organ preservation has become an attractive alternative to surgery (total mesorectal excision [TME]) among patients with rectal cancer after neoadjuvant therapy who achieve a clinical complete ...

Jonathan W. Friedberg, MD, University of Rochester, Rochester, NY, USA ...

Combination of Osimertinib and Vascular Endothelial Growth Factor Receptor Inhibitors for EGFR-Mutated Non–Small Cell Lung Cancer: Old or New Regimen? Clinical trials frequently include multiple end ...

JCO is the primary forum of scientific discourse for the American Society of Clinical Oncology (ASCO). Published three times a month, JCO is the foremost peer-reviewed journal focusing on clinical ...

Changes in the Epidemiologic Pattern of Primary CNS Tumors in Response to the Aging Population: An Updated Nationwide Cancer Registry Data in the Republic of Korea Changes in ferritin, lactate ...

Low- and middle-income countries (LMICs) report disproportionally worse cancer mortality. Current global cancer control efforts focus predominantly on expanding access to multimodality treatment for ...

In the article that accompanies this editorial, Wu et al 36 observed that residential exposure to fine particulate matter was associated with higher breast cancer incidence using prospective data from ...

Comprehensive Genomic Assessment of Advanced-Stage GI Stromal Tumors Using the Japanese National Center for Cancer Genomics and Advanced Therapeutics Database We analyzed the genomic and immune ...

Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer The median follow-up for censored patients was 7.9 years. According to NCCN risk ...

UGT1A1 Testing for the Risk of Nanoliposomal Irinotecan–Related Toxicity Phase III trials that randomly assign patients to a control treatment (C), an experimental treatment (A), or a combination ...